This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Non-Hodgkin lymphoma
  • /
  • Guideline for the management of mantle cell lympho...

Guideline for the management of mantle cell lymphoma

Read time: 1 mins
Last updated:15th May 2018
Guideline for the management of mantle cell lymphoma - British Society for Haematology (BSH)

Mantle cell lymphoma (MCL) is a B cell malignancy with unique biological, pathological and clinical features comprising 3–10% of all non-Hodgkin lymphomas (NHLs) (Swerd-low et al, 1983). It was recognised as a specific entity in the revised European-American classification of lymphoid neo-plasms (REAL) classification (Harris et al, 1994) and is characterized by the chromosomal translocation t(11;14)(q13-3;q32-33), resulting in over-expression of the cell cycle protein cyclin D1 (Akiyama et al, 1994; Campo et al, 1999).

The aim is to provide healthcare professionals with guidance on the management of patients with mantle cell lymphoma (MCL). Individual patient circumstances may dictate an alternative approach. This is an update of the guidance published in 2012 (McKay et al, 2012), incorporating new therapeutic options, including transplant data. Developments in pathology, in particular molecular pathology and use of positron emission tomography/computed tomography (PET/CT) scanning in staging and response assessment are now covered in a separate Good Practice Paper (McKay et al, 2018).


Read full guideline